Ashley Koegel, Global Program Lead for In Vivo Cellular Therapy at Bristol Myers Squibb shared a post on LinkedIn:
“Honored to have served as a co‑organizer for the 2026 Society for Immunotherapy of Cancer (SITC) Spring Scientific Summit with the Society for Immunotherapy of Cancer (SITC) alongside Kristen Hege, Daniel Powell, Gordon Moody, and Evan Weber.
Leaders from across academia and industry came together to push the boundaries of next-generation cellular therapies, T cell engagers, and combination strategies that would have seemed ambitious just a few years ago. The level of science, rigor of discussion, and collective momentum were truly energizing and a reminder of how fast this field is moving.
Huge thanks to my fellow organizers, the exceptional speakers, and the SITC team for making this such a high‑impact and energizing program. Already looking forward to what’s next for the field.”
Society for Immunotherapy of Cancer (SITC) shared the post, adding:
“Thanks Dr. Ashley Koegel for your leadership in helping to create an incredible event. Hats off to all of the organizers, faculty, supporters, exhibitors and attendees for another inspiring Spring Scientific.
We are looking forward to seeing everyone at SITC 2026!”
Other articles featuring Ashley Koegel on OncoDaily.